Where does Prognosys Biosciences, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Prognosys Biosciences, Inc. ranks #4,785 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Prognosys Biosciences, Inc. hold?

Prognosys Biosciences, Inc. holds 73 US utility patents granted between 2015 and 2025, spanning 8 technology areas.

What is Prognosys Biosciences, Inc.'s Innovation Score?

Prognosys Biosciences, Inc. has an Innovation Score of 46.5 out of 100 (top 21% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Prognosys Biosciences, Inc.'s patent grant rate increasing or decreasing?

Prognosys Biosciences, Inc.'s recent grant velocity is +178% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Prognosys Biosciences, Inc.'s patents?

Prognosys Biosciences, Inc.'s patents average 26.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Prognosys Biosciences, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Prognosys Biosciences, Inc.

Q: What technology areas does Prognosys Biosciences, Inc. focus on?

Prognosys Biosciences, Inc.'s top technology area is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes) with 71 patents, ranking #59 of 2,502 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

USPTO PatentsView assignee record - 73 granted patents across 8 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Prognosys ranks #4,785 of 49,997 tracked US assignees by granted-patent volume, with 73 patents across 8 technology areas.

#4,785
of 49,997 US assignees by volume: Top 21%
by Innovation Score (46.5/100): 26.5
avg claims per patent: +178%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4785 · US Corporation #4,785 · 73 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 73 grants
TOP-DECILE #4,785/49,997
PHOTO-FINISH Nerviano Medical…
CPC-NARROW C12Q · 8 areas
INNOV-PAR 46.5/100
CLAIMS-DENSE 26.5 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +178% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Nerviano Medical Sciences S.R.L. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Prognosys’s 46.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.9 pts (32%) Velocity 6.7 pts (14%) Breadth 10.0 pts (21%) Claim depth 15.0 pts (32%)

Qualcomm Incorporated · highest

85
ABB Technology Oy · near

47
College DE France · near

47
Edge 3 · near

47
KA Group · near

47
Prognosys Biosciences · this assignee

47
3D Lighting… · lowest

7

What this shows Prognosys's Innovation Score is 46.5/100 (top 21% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Prognosys?

Each dot is one of Prognosys’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Prognosys’s own 26.5 claims/patent is ABOVE the 14.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Prognosys vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Prognosys's grants concentrate

Prognosys Biosciences, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 97.3% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2022 (16 grants) versus a trough of 1 in 2016. By volume, Prognosys sits between Nerviano Medical Sciences S.R.L. and Sigma Computing, Inc..

Prognosys's three-year grant acceleration

From 2019–2021 to 2022–2024, Prognosys Biosciences, Inc. moved from 29 to 29 grants (1.00x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Nerviano Medical…

73
Purdue Pharmaceut…

73
Performance Desig…

73
Pride Mobility Pr…

73
Qingdao Haier Dru…

73
Rackspace US

73
Rheinisch-westfäl…

73
Sigma Computing

73
Prognosys Bioscie… ◀

73

What this shows Prognosys holds 73 patents at rank #4,786, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Prognosys

By rank, the assignees closest to #4,786 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Prognosys's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Prognosys, neither rank-band nor same-CPC leaders (those blocks stay above). In C12Q (Measuring OR Testing Processes Involving Enzymes), Prognosys ranks #59 of 2,502 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (47 here).

Edge 3 Technologies 47 ABB Technology Oy 47 KA Group AG 47 College DE France 47

Similar claim depth

Nearest assignees by average claims per patent (26.5 here).

10x Genomics, Inc. 26.5 avg iCometrue Company Ltd. 26.4 avg PPC Broadband, Inc. 26.4 avg Beijing Research Institute OF Chemical Industry, China Petroleum & Chemical Corporation 26.5 avg

Prognosys's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

47 Top 21% higher than 79% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Prognosys Biosciences, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	4.1%
2016	1	1.4%
2017	1	1.4%
2018	5	6.8%
2019	8	11.0%
2020	6	8.2%
2021	15	20.5%
2022	16	21.9%
2023	11	15.1%
2024	2	2.7%
2025partial year	5	6.8%

Which technologies does Prognosys Biosciences, Inc. patent most?

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 71

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 53

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 50

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 46

C07K - Peptides 3

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 2

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Prognosys Biosciences, Inc.'s patent record in context - here's where to go next.

Prognosys Biosciences, Inc.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 97.3% of its portfolio - see every assignee active in that class. Explore C12Q
Ranked #4,785 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Prognosys Biosciences, Inc. against Nerviano Medical Sciences S.R.L., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 46.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.